CN1868507B - Medicine composition, preparation method and application thereof - Google Patents
Medicine composition, preparation method and application thereof Download PDFInfo
- Publication number
- CN1868507B CN1868507B CN2005100436261A CN200510043626A CN1868507B CN 1868507 B CN1868507 B CN 1868507B CN 2005100436261 A CN2005100436261 A CN 2005100436261A CN 200510043626 A CN200510043626 A CN 200510043626A CN 1868507 B CN1868507 B CN 1868507B
- Authority
- CN
- China
- Prior art keywords
- extract
- salvianolic acid
- paeony
- pharmaceutical composition
- total glucosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A medicinal composition used to prepare the medicines for preventing and treating cardiovascular and cerebrovascular diseases contains danshinolic acid and paeoniflorin in ratio of (1-5): (5-1). Its preparing process is also disclosed.
Description
Technical field:
The present invention relates to a kind of pharmaceutical composition and its production and use, relating to salvianolic acid and Radix Paeoniae Alba total glycosides particularly is pharmaceutical composition of active component and its production and use.
Background technology:
Salvianolic acid extracts acquisition from Radix Salviae Miltiorrhizae, its main component is salvianolic acid B, rosmarinic acid, danshensu, protocatechualdehyde etc.Salvianolic acid aspect cardiovascular and cerebrovascular disease, all have the certain protection effect [Ren Decheng, Du Guanhua, Zhang Juntian. total salvianolic acid is to the protective effect of cerebral ischemia reperfusion injury. Chinese Pharmacological circular, 2002,18 (3): 275～277.; Xu Jiangping, Sun Lisha, Wu Hangyu, etc. salvianolic acid B is to the protective effect of rat heart muscle ischemia reperfusion injury. Chinese Pharmaceutical Journal, 2003,38 (8): 595～597.].
Peoniflorin (Paeoniflorin) is mainly derived from medical materials such as medical material Radix Paeoniae Rubra, the Radix Paeoniae Alba, Cortex Moutan, is its main effective ingredient.Report such as Wei Shoujian paeoniflorin is to the protection and the Mechanism Study [Chinese tcm emergency, 2000,9 (6): 274-276.] of PC12 cell ischemia injury; Zhang Guangqin etc. think that peoniflorin is to the blocking effect of rat myocardial cell L calcium channel [Chinese Pharmacological circular, 2003,19 (8): 863-866.]; Yang Jun etc. have reported the protective effect [Chinese Journal of New Drugs of peoniflorin to potassium chloride and the inductive PC12 cell calcium overload of N-methyl D-Aspartic Acid damage, 2001,10 (6): 426-428.] Yang Jun has carried out studying [Medical University Of Anhui's journal to Radix Paeoniae Rubra total glycosides treatment ischemic cerebrovascular effect and mechanism thereof, 2001,36 (2): 164.]; Xu Hongmei has reported total paeony glycoside anti thrombotic action [Anhui Chinese Medicine College journal, 2000,19 (1): 46-47.].
The inventor, has synergism, and then has finished the present invention when finding to be used for cardiovascular and cerebrovascular disease after salvianolic acid and extract product of paeoniflorin make up by a large amount of experimentatioies.
Summary of the invention:
The invention provides a kind of is the pharmaceutical composition of active component with salvianolic acid extract and extract of total glucosides of paeony, 100%＞salvianolic acid (in salvianolic acid B) 〉=50% in the salvianolic acid extract wherein, be preferably 100%＞salvianolic acid (in salvianolic acid B) 〉=80%, 100%＞Radix Paeoniae Alba total glycosides content in the extract of total glucosides of paeony) 〉=50%, 100%＞paeoniflorin content 〉=40%, be preferably 100%＞Radix Paeoniae Alba total glycosides content 〉=80%, 100%＞paeoniflorin content 〉=60%, the portion rate of salvianolic acid and extract product of paeoniflorin is 1: 9～9: 1, is preferably 1: 5～5: 1.
The invention provides with salvianolic acid and extract product of paeoniflorin is the preparation of drug combination method of active component.
The invention provides with salvianolic acid and extract product of paeoniflorin is the application of pharmaceutical composition in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease of active component.
The invention provides with salvianolic acid and extract product of paeoniflorin is the application of pharmaceutical composition in preparing medicines such as treatment or prevention coronary heart disease, angina pectoris, cardiac-cerebral ischemia of active component.
Pharmaceutical composition of the present invention, wherein salvianolic acid can by but be not limited to from red rooted salvia, extract; Extract product of paeoniflorin can by but be not limited to from Cortex Moutan, Radix Paeoniae Rubra or the Radix Paeoniae Alba, extract.
The pharmaceutical composition that the present invention proposes can be injection, injectable powder, tablet, capsule, granule, oral liquid, microgranule, preferred lyophilized injectable powder, and used adjuvant is the conventional adjuvant of various preparations.
Pharmaceutical composition provided by the invention is when being used for cardiovascular and cerebrovascular disease, and its using dosage scope is 60mg～6000mg, is preferably 60mg～2000mg.
The salvianolic acid extract that the present invention proposes can by but be not limited to following method and make: get the Radix Salviae Miltiorrhizae crude drug and pulverize, adding a certain amount of sour water percolation extracts, filter, adsorb, use the deionized water eluting with macroporous adsorbent resin, reuse Diluted Alcohol eluant solution, collect eluent, regulate acidity 2～5, concentrate ethanol, lyophilizing gets the salvianolic acid extract.
The extract of total glucosides of paeony that the present invention proposes can by but be not limited to following method and make: get the Cortex Moutan pulverizing medicinal materials, water heating extraction 2 times is filtered, cooling is adsorbed with macroporous adsorbent resin, and water fully is eluted to effluent for after clarification and not having reducing sugar reaction, reuse Diluted Alcohol eluant solution, collect eluent, concentrating under reduced pressure is closely dried, and reuse ethanol is refining, filter, reclaim ethanol, polyamide chromatography column purification is drying to obtain extract of total glucosides of paeony on the concentrated solution.
The inventor has carried out following test and has confirmed with salvianolic acid and extract product of paeoniflorin to be the effect of pharmaceutical composition in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease of active component, and its effect far is better than singly to be used with dosage salvianolic acid or extract product of paeoniflorin, but is not limited only to this.
Concrete embodiment:
Preparation example 1: preparation salvianolic acid and extract product of paeoniflorin
Getting 10kg Radix Salviae Miltiorrhizae crude drug pulverizes, 30 times of amount sour water percolation extract, filter, adsorb (weight ratio of medical material and resin 1: 3), with deionized water eluting 4 column volumes with the AB-8 macroporous adsorbent resin, 5 column volumes of the alcoholic solution eluting of reuse 50%, collect eluent, regulating pH value is 3, concentrates ethanol, lyophilizing, getting salvianolic acid (in salvianolic acid B) content is 52%.
Get 10kg Cortex Moutan pulverizing medicinal materials, 10 times of water gaging heating extraction 2 times are filtered, cooling is adsorbed with macroporous adsorbent resin, and water fully is eluted to effluent for after clarification and not having reducing sugar reaction, reuse Diluted Alcohol eluant solution is collected eluent, and concentrating under reduced pressure is closely dried, reuse ethanol is refining, filters, and reclaims ethanol, polyamide chromatography column purification on the concentrated solution, the dry extract product of paeoniflorin that gets, wherein Cortex Moutan total glycosides (in peoniflorin) content is 65%, paeoniflorin content is 57%.
Preparation example 2: preparation salvianolic acid extract and extract of total glucosides of paeony
Getting 10kg Radix Salviae Miltiorrhizae crude drug pulverizes, 30 times of amount sour water percolation extract, filter, adsorb (weight ratio of medical material and resin 1: 3), with deionized water eluting 6 column volumes with the AB-8 macroporous adsorbent resin, 4 column volumes of the alcoholic solution eluting of reuse 30%, collect eluent, regulating pH value is 2, concentrates ethanol, lyophilizing, getting salvianolic acid (in salvianolic acid B) content is 83%.
Get 10kg Cortex Moutan pulverizing medicinal materials, 10 times of water gaging heating extraction 2 times, filter, cooling, adsorb with 4 times of amounts (amount of resin and medical material amount) macroporous adsorbent resin, water fully is eluted to effluent for after clarification and not having reducing sugar reaction, and reuse 40% alcoholic solution eluting is collected eluent, concentrating under reduced pressure is closely dried, reuse 80% ethanol is refining, filters, and reclaims ethanol, polyamide chromatography column purification on the concentrated solution, the dry extract product of paeoniflorin that gets, wherein Radix Paeoniae Alba total glycosides (in peoniflorin) content is 84%, paeoniflorin content is 76%.
Preparation example 3: preparation is the freeze-dried powder of active component with salvianolic acid and extract product of paeoniflorin
Get salvianolic acid extract (salvianolic acid content is 83%) 30g, (Radix Paeoniae Alba total glycosides is 84% in peoniflorin content to extract of total glucosides of paeony, wherein paeoniflorin content is 76%) 30g adds injection water 2000ml after mixing, with mannitol 8g, stirring and dissolving, ultrafiltration, obtain apyrogenic clear liquor, pour in the 10ml cillin bottle, 2ml/ only, press the lyophilizing of freeze-dried powder technology, make freeze-dried powder.
Get salvianolic acid extract (salvianolic acid content is 52%) 30g, (the Cortex Moutan total glycosides is 65% in peoniflorin content to extract of total glucosides of paeony, wherein paeoniflorin content is 57%) 30g adds injection water 2000ml after mixing, with mannitol 8g, stirring and dissolving, ultrafiltration, obtain apyrogenic clear liquor, pour in the 10ml cillin bottle, 2ml/ only, press the lyophilizing of freeze-dried powder technology, make freeze-dried powder.
Test example 1: pharmaceutical composition of the present invention is to the influence of rat heart muscle ischemic injuries
(1) material:
Salvianolic acid, extract product of paeoniflorin are by the preparation of preparation example 2 methods.
Compositions: take by weighing salvianolic acid, extract product of paeoniflorin is an amount of, the ratio and the concentration that need in the test requirements document preparation.
Chlorination nitro blue tetrazolium (N-BT) is provided by Military Medical Science Institute medical supply station.
Laboratory animal: regular grade SD rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into model control group (normal saline) at random, Nifedipine group (6mg/kg), salvianolic acid group (3mg/kg), salvianolic acid group (6mg/kg), extract product of paeoniflorin group (3mg/kg), extract product of paeoniflorin group (6mg/kg), salvianolic acid extract (0.6mg/kg)+extract of total glucosides of paeony (5.4mg/kg) dosage group, salvianolic acid extract (5.4mg/kg)+extract of total glucosides of paeony (0.6mg/kg) dosage group, salvianolic acid extract (1mg/kg)+extract of total glucosides of paeony (5mg/kg) dosage group, salvianolic acid extract (5mg/kg)+extract of total glucosides of paeony (1mg/kg) dosage group, salvianolic acid extract (3mg/kg)+extract of total glucosides of paeony (3mg/kg) dosage group, salvianolic acid extract (2mg/kg)+extract of total glucosides of paeony (4mg/kg) dosage group, salvianolic acid extract (4mg/kg)+extract of total glucosides of paeony (2mg/kg) dosage group, salvianolic acid extract (30mg/kg)+extract of total glucosides of paeony (30mg/kg) dosage group, salvianolic acid extract (15mg/kg)+extract of total glucosides of paeony (15mg/kg) oral dose group, salvianolic acid extract (100mg/kg)+extract of total glucosides of paeony (100mg/kg) oral dose group, salvianolic acid extract (300mg/kg)+extract of total glucosides of paeony (300mg/kg) oral dose group.Every group 10.After the fasting 12 hours, limbs II lead electrocardiogram is surveyed in ip. urethane (1.2g/kg) anesthesia.Cut off left front fur, iodine tincture and alcohol disinfecting, control left border of sternum 1cm place, cut off thoracic wall muscle and two ribs, open the thoracic cavity rapidly, expose heart, the ligation left coronary artery is put back to heart immediately between arterial cone and left auricle, squeezes the thoracic cavity air, use the mosquito forceps closed-chest, cause Model Rats with Acute Myocardial Ischemia.Nifedipine group is gastric infusion before anesthesia, composition oral dosage group successive administration 3 days, and fasting is after 16 hours after administration in the 2nd day, and administration in the 3rd day was performed the operation after 30 minutes, and all the other respectively organize postoperative with both intravenous injection relative medicines.1.5h, 3h electrocardiogram before the record administration and after the administration measure the lift-off value of electrocardiogram J point, take out heart behind the 6h, with cold saline clean after ,-20 ℃ of refrigerator freeze overnight.Next day, refrigerated heart is cut into 5 by ligation place to apex uniform thickness, immerse in the freshly prepared 0.25%N-BT phosphate buffer (pH 7.4).37 ℃ of water-bath jolting 10～15min.Blot the dyeing liquor of slice surface with filter paper, separate the coloured portions and the part of being unstained, weigh the compute infarct size.Infarct size (%)=infarction part weight/(non-infarction part weight+infarction part weight) * 100%.Data are represented with X ± s, carry out statistical procedures with t check between group.
The result is as shown in table 1, and myocardial ischemia is after 6 hours, and tangible kitchen range shape ischemic region appears in the model group rat heart muscle, reaches about 26%.3mg/kg salvianolic acid and 3mg/kg extract product of paeoniflorin group fail to reduce rising, the minimizing ischemic areas of limb lead electrocardiogram J point; 6mg/kg salvianolic acid extract and 6mg/kg extract of total glucosides of paeony group, composition oral dosage group [salvianolic acid (15mg/kg)+extract product of paeoniflorin (15mg/kg)] all reduce rising, the minimizing ischemic areas (comparing p＜0.05 with model group) of limb lead electrocardiogram J point to a certain extent; Composition dosage group 1[salvianolic acid extract (0.6mg/kg)+extract of total glucosides of paeony (5.4mg/kg)], composition dosage group 2[salvianolic acid extract (1mg/kg)+extract of total glucosides of paeony (5mg/kg)], composition dosage group 3[salvianolic acid extract (5.4mg/kg)+extract of total glucosides of paeony (0.6mg/kg)], composition dosage group 4[salvianolic acid extract (5mg/kg)+extract of total glucosides of paeony (1mg/kg)], composition dosage group 5[salvianolic acid extract (3mg/kg)+extract of total glucosides of paeony (3mg/kg)], composition dosage group 6[salvianolic acid extract (2mg/kg)+extract of total glucosides of paeony (4mg/kg)], composition dosage group 7[salvianolic acid extract (4mg/kg)+extract of total glucosides of paeony (2mg/kg)] reduce the rising of limb lead electrocardiogram J point significantly, reducing ischemic areas (compares with model group, p＜0.01), composition dosage group 1, composition dosage group 2, composition dosage group 3, composition dosage group 4, composition dosage group 5, composition dosage group 6, the rising of 7 pairs of limb lead electrocardiogram J points of composition dosage group, reduce ischemic areas and 6mg/kg salvianolic acid extract group, 6mg/kg extract of total glucosides of paeony group more also has significant difference (p＜0.05); Composition dosage group 8, composition dosage group 10, composition dosage group 11 reduce rising, the minimizing ischemic areas (comparing p＜0.001 with model group) of limb lead electrocardiogram J point extremely significantly; Composition dosage group 10 compares with composition dosage group 11, to the rising and the ischemic areas no significant difference (p＞0.05) of limb lead electrocardiogram J point.
Table 1 salvianolic acid extract, extract of total glucosides of paeony, compositions are to the influence of rat heart muscle ischemic injuries
Compare with model control group,
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Compare with dosage group in the salvianolic acid,
#P＜0.05; Compare with dosage group in the extract product of paeoniflorin,
MP＜0.05
Test example 2: the present composition is to the influence of rat local cerebral ischemia damage
(1) material:
Salvianolic acid extract, extract product of paeoniflorin are by the preparation of preparation example 2 methods.
Compositions: take by weighing salvianolic acid, extract product of paeoniflorin is an amount of, the ratio and the concentration that need in the test requirements document preparation.
Red tetrazolium: U.S. Sigma company product, face with preceding and be made into 4% solution with normal saline.
Laboratory animal: regular grade Wistar rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into model control group (normal saline) at random, nimodipine group (1.0mg/kg), salvianolic acid extract group (3mg/kg), salvianolic acid extract group (6mg/kg), extract of total glucosides of paeony group (3mg/kg), extract of total glucosides of paeony group (6mg/kg), salvianolic acid extract (0.6mg/kg)+extract of total glucosides of paeony (5.4mg/kg) dosage group, salvianolic acid extract (5.4mg/kg)+extract of total glucosides of paeony (0.6mg/kg) dosage group, salvianolic acid extract (1mg/kg)+extract of total glucosides of paeony (5mg/kg) dosage group, salvianolic acid extract (5mg/kg)+extract of total glucosides of paeony (1mg/kg) dosage group, salvianolic acid extract (3mg/kg)+extract of total glucosides of paeony (3mg/kg) dosage group, salvianolic acid extract (2mg/kg)+extract of total glucosides of paeony (4mg/kg) dosage group, salvianolic acid extract (4mg/kg)+extract of total glucosides of paeony (2mg/kg) dosage group, salvianolic acid extract (30mg/kg)+extract of total glucosides of paeony (30mg/kg) dosage group, salvianolic acid extract (15mg/kg)+extract of total glucosides of paeony (15mg/kg) oral dose group, salvianolic acid extract (100mg/kg)+extract of total glucosides of paeony (100mg/kg) oral dose group, salvianolic acid extract (300mg/kg)+extract of total glucosides of paeony (300mg/kg) oral dose group.Every group 10.Every group 10.After the fasting 12 hours, and chloral hydrate (350mg/kg, i.p.) anesthesia separates right carotid, and folder closes in the neck, common carotid artery, external carotid artery proximal part and distal end ligation, cut off the centre.The external carotid artery free-end is pulled to internal carotid artery in alignment, bolt line (selecting diameter 0.24mm nylon wire for use, length 5.0cm) is inserted into intracranial by external carotid artery, stop when meeting slight resistance, insertion depth is about 2cm.Ligation external carotid artery opening, and open the common carotid artery bulldog clamp, the disinfection and stitching wound causes right side middle cerebral artery ischemia model; Sham operated rats is only carried out the separation (above experiment is all carried out at 23 ℃～25 ℃) of right carotid, internal carotid artery, external carotid artery.Composition oral dosage group successive administration 3 days, fasting is after 16 hours after administration in the 2nd day, and administration in the 3rd day was performed the operation after 30 minutes, and all the other respectively organize postoperative intravenous injection relative medicine.Press document [Liu Xiaoguang, Xu Lina, a kind of rat brain medium-sized artery model that can estimate thrombolytic and anti-thrombolytic after 24 hours, Acta Pharmaceutica Sinica, 1995,30:662] described method and standard is observed and the behavior disorder of record rat: (A) carry the Mus tail and observe forelimb flexing situation, stretch to ground as two forelimb symmetries, count 0 fen, the wrist flexing occurs as operation offside forelimb and count 1 fen, the elbow flexing is counted 2 fens, the shoulder inward turning is counted 3 fens, existing wrist flexing and/or elbow flexing have shoulder inward turning person again, count 4 fens.(B) animal is placed on the plane earth, push away both shoulders respectively, check resistance to side shifting.As bilateral resistance equity and strong, count 0 fen, as resistance descender when the operation offside promotes, according to decline degree difference be divided into gently, in, weigh three degree, count 1,2 and 3 fen respectively.(C) the two forelimbs of animal are put on the wire netting, observed the muscular tension of two forelimbs.Two muscle of anterior limb tension force equities and strong person count 0 fen.Count 1,2 and 3 fen according to operation offside muscular tension decline degree difference equally.(D) animal has ceaselessly to a side person of turn-taking, and counts 1 fen.According to the standard scoring, full marks are 11 minutes, and mark is high more, and expression animal behavior obstacle is serious more.
Put to death rat behind the behavior scoring, get brain, remove olfactory bulb, cerebellum and low brain stem, crownly be cut into 5, the brain sheet takes on a red color after normal structure is dyed with red tetrazolium (TTC) dyeing, and blocking tissue is white in color, taking a picture in dyeing back, asks the infarct size ratio with Chinese Aero-Space university pathological image analysis software.Data are represented with X ± s, carry out statistical procedures with t check between group.
The result is as shown in table 2, and ischemia is after 24 hours, and the model group rat shows tangible behavior disorder, and tangible kitchen range shape ischemic region also appears in rat cerebral tissue, reaches full brain about 24%.3mg/kg salvianolic acid extract and 3mg/kg extract of total glucosides of paeony group are failed to improve the rat behavior obstacle, are reduced ischemic areas; 6mg/kg salvianolic acid extract and 6mg/kg extract of total glucosides of paeony group, salvianolic acid extract (15mg/kg)+extract of total glucosides of paeony (15mg/kg) oral dose group are all improved the rat behavior obstacle to a certain extent, are reduced ischemic areas (comparing p＜0.05 with model group); Composition dosage group 1[salvianolic acid extract (0.6mg/kg)+extract of total glucosides of paeony (5.4mg/kg)], composition dosage group 2[salvianolic acid extract (1mg/kg)+extract of total glucosides of paeony (5mg/kg)], composition dosage group 3[salvianolic acid extract (5.4mg/kg)+extract of total glucosides of paeony (0.6mg/kg)], composition dosage group 4[salvianolic acid extract (5mg/kg)+extract of total glucosides of paeony (1mg/kg)], composition dosage group 5[salvianolic acid extract (3mg/kg)+extract of total glucosides of paeony (3mg/kg)], composition dosage group 6[salvianolic acid extract (2mg/kg)+extract of total glucosides of paeony (4mg/kg)], composition dosage group 7[salvianolic acid extract (4mg/kg)+extract of total glucosides of paeony (2mg/kg)] significantly improve the rat behavior obstacle, reducing ischemic areas (compares with model group, p＜0.01), composition dosage group 1, composition dosage group 2, composition dosage group 3, composition dosage group 4, composition dosage group 5, composition dosage group 6,7 pairs of composition dosage groups are improved the rat behavior obstacle, reduce ischemic areas and 6mg/kg salvianolic acid extract group, 6mg/kg extract of total glucosides of paeony group relatively also has significant difference (p＜0.05); Composition dosage 8, composition dosage 10, composition dosage 10 are improved the rat behavior obstacle extremely significantly, are reduced ischemic areas (comparing p＜0.001 with model group); Composition dosage group 10 compares with composition dosage group 11, to improving the rat behavior obstacle, reducing ischemic areas no significant difference (p＞0.05).
Table 2 salvianolic acid, extract product of paeoniflorin and compositions thereof are to the influence of rat cerebral ischemia damage
Compare with model control group,
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Compare with dosage group in the salvianolic acid,
#P＜0.05; Compare with dosage group in the extract product of paeoniflorin,
MP＜0.05
Claims (10)
1. one kind is the pharmaceutical composition of active component with salvianolic acid extract and extract of total glucosides of paeony, wherein in the salvianolic acid extract 100%＞in salvianolic acid B salvianolic acid content 〉=50%, 100%＞Radix Paeoniae Alba total glycosides content 〉=50% in the extract of total glucosides of paeony, 100%＞paeoniflorin content 〉=40%, the portion rate of salvianolic acid extract and extract of total glucosides of paeony are 1: 9～9: 1.
2. pharmaceutical composition according to claim 1 is characterized by: the portion rate of salvianolic acid extract and extract of total glucosides of paeony is 1: 5～5: 1.
3. pharmaceutical composition according to claim 1 and 2, it is characterized by: in the salvianolic acid extract 100%＞in salvianolic acid B salvianolic acid content 〉=80%, it in the extract of total glucosides of paeony 100%＞Radix Paeoniae Alba total glycosides content 〉=80%, 100%＞paeoniflorin content 〉=60%.
4. pharmaceutical composition according to claim 1 and 2, the salvianolic acid preparation method of extract is: get the Radix Salviae Miltiorrhizae crude drug and pulverize, add a certain amount of sour water percolation and extract, filter, adsorb with macroporous adsorbent resin, use the deionized water eluting, reuse Diluted Alcohol eluant solution is collected eluent, regulate acidity 2～5, concentrate ethanol, lyophilizing gets the salvianolic acid extract.
5. pharmaceutical composition according to claim 4, the salvianolic acid preparation method of extract is: get the Radix Salviae Miltiorrhizae crude drug and pulverize, 30 times of amount sour water percolation extract, filter, adsorb with the AB-8 macroporous adsorbent resin, the weight ratio of medical material and resin is 1: 3, with deionized water eluting 4 column volumes, 5 column volumes of the alcoholic solution eluting of reuse 50%, collect eluent, regulating pH value is 3, concentrates ethanol, lyophilizing, promptly.
6. pharmaceutical composition according to claim 4, the salvianolic acid preparation method of extract is: get the Radix Salviae Miltiorrhizae crude drug and pulverize, 30 times of amount sour water percolation extract, filter, adsorb with the AB-8 macroporous adsorbent resin, the weight ratio of medical material and resin is 1: 3, with deionized water eluting 6 column volumes, 4 column volumes of the alcoholic solution eluting of reuse 30%, collect eluent, regulating pH value is 2, concentrates ethanol, lyophilizing, promptly.
7. pharmaceutical composition according to claim 1 and 2, it contains the active component of 60mg～6000mg.
8. the application of the arbitrary described pharmaceutical composition of claim 1-7 in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease.
9. application according to claim 8, the application of pharmaceutical composition in preparation treatment or prevention coronary heart disease or anginal medicine.
10. application according to claim 8, the application of pharmaceutical composition in the medicine of preparation treatment or prevention cardiac-cerebral ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100436261A CN1868507B (en) | 2005-05-25 | 2005-05-25 | Medicine composition, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100436261A CN1868507B (en) | 2005-05-25 | 2005-05-25 | Medicine composition, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1868507A CN1868507A (en) | 2006-11-29 |
| CN1868507B true CN1868507B (en) | 2011-09-14 |
Family
ID=37442373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100436261A Expired - Fee Related CN1868507B (en) | 2005-05-25 | 2005-05-25 | Medicine composition, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1868507B (en) |
-
2005
- 2005-05-25 CN CN2005100436261A patent/CN1868507B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 任德成，杜冠华，张均田.总丹酚酸对缺血性再灌注损伤的保护作用.中国药理学通报18 3.2002,18(3),275-277. |
| 任德成,杜冠华,张均田.总丹酚酸对缺血性再灌注损伤的保护作用.中国药理学通报18 3.2002,18(3),275-277. * |
| 杨军，马传庚.赤芍总苷治疗缺血性脑血管作用及其机制.安徽医科大学学报36 2.2001,36(2),164-165. |
| 杨军,马传庚.赤芍总苷治疗缺血性脑血管作用及其机制.安徽医科大学学报36 2.2001,36(2),164-165. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1868507A (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003260985B2 (en) | Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug | |
| JP2007505936A (en) | Pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases | |
| CN101342274B (en) | Curculigo orchioides extract, preparation method and uses thereof | |
| CN101596182A (en) | Contain pharmaceutical composition, its preparation method, the purposes of salviol acid A and contain the lyophilized injectable powder and the aqueous injection of said composition | |
| CN102274260B (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| CN101156863B (en) | A medicine composition for treating cardiac and cerebral vascular disease and its medical usage | |
| CN107412430A (en) | A kind of radix scrophulariae water extract and its application | |
| CN101675934B (en) | New use of saponins X of dipsacus asperoides | |
| CN100512796C (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN1868507B (en) | Medicine composition, preparation method and application thereof | |
| CN1686424B (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN102526147A (en) | Method for purifying panax notoginseng total saponins and preparation of panax notoginseng total saponins | |
| CN1868508B (en) | Medicine composition, application of the same for preparing medicine to treat and prevent cardiovascular and cerebrovascular disease | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| KR20070017944A (en) | Radix salviae miltiorrhizae?extract and composition thereof for the treatment of the aspirin resistance diseases | |
| CN100577184C (en) | Medicine composition and use thereof | |
| CN103191167A (en) | Application of eupatorium Chinese | |
| CN1326520C (en) | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease | |
| CN100551372C (en) | A kind of pharmaceutical composition and the application in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease thereof | |
| CN1911219B (en) | Medicine composition, and its application | |
| CN100486578C (en) | Medicine composition and its application in preparation of medicine for treating or preventing cardiovascular and cerebrovascular diseases | |
| CN100400074C (en) | Chinese medicinal preparation for freating coronary heart disease, brain arteriosclerosis and its preparation method | |
| CN101485671B (en) | Novel medicinal use of 8-O-acetyl shanzhiside methylester | |
| CN101023983A (en) | Medicine composition and use | |
| CN100450496C (en) | Compound preparation of notoginseng and safflower for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170613 Address after: 264670, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Patentee after: Shandong Luye Pharma Co., Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20180525 |